Rita C. Peters

CPhI Pharma Awards honor companies and individuals driving the pharma industry forward.

Reeling from financial and tropical storms, Puerto Rico needs stable industry to aid its recovery.

Amid debate about “fake news,” peer-review papers offer vital, objective insight.

New reports address biopharma’s leading concerns: funding for drug development and pricing of finished drugs.

New study will reveal bio/pharma practices and performance on quality issues.

Philadelphia plays host to the exhibits, conferences, and networking activities of CPhI North America on May 16-18, 2017.

Report: Global medicine spending will reach nearly $1.5 trillion by 2021.

Rookie API developers beat pharma at its own game.

Job security may have increased, but biopharma professionals remain somewhat dissatisfied with pay levels.

CPhI Pharma Award winners were recognized for sweating the details for the bigger picture.

BioPharm International editors seek bioprocessing experts to contribute technical articles in 2017.

Steep price increases for a popular drug have created patient and Congressional backlash.

Congressional partisanship creates noise, but no funding for Zika virus research.

CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.

Advances in single-use systems, consumables, and continuous manufacturing show steady progress.

Proven science-based strategies can help to accelerate vaccine development.

Thought leaders tackle drug shortages and biomanufacturing challenges.

Report: Biologics contribute to rebirth of biopharma innovation.

FDA approved 45 novel new drugs in 2015, led by therapies for orphan diseases and and expedited approvals.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016.

Biopharma employees in different market segments note subtle differences in job satisfaction.

Limited career and salary growth complicate a somewhat positive employment picture.

Biopharma and contract providers must tread carefully amid changing market dynamics.

FDA notes progress in drug development, but cites scientific and funding roadblocks.

As biopharma enjoys success, it cannot ignore pressing patient access questions.

Objective, peer-reviewed papers and technical articles can help advance biopharmaceutical development.

The biopharma industry has had some successes but still needs to work on operational issues.

FDA approves a biosimilar and loses a commissioner in March.

Sessions address cell therapies, serialization, contract services, and more.